Abstract
Bacillus Calmette Guérin (BCG) vaccination use in the fight against COVID-19 - what's old is new again?
Highlights
Bacillus Calmette Guerin (BCG) is a vaccine derived from the live attenuated strain of Mycobacterium bovis and used widely as a vaccination against tuberculosis in high-risk regions
Three new clinical trials have commenced recruitment aiming to test the hypothesis that BCG vaccination may be protective against COVID-19 in healthcare workers
The primary outcome measures in each study differ; the Australian and American groups looking to evaluate the incidence of COVID-19 and severity of symptoms from disease and the Dutch group primarily looking at healthcare worker absenteeism [10,11,12]
Summary
Bacillus Calmette Guerin (BCG) is a vaccine derived from the live attenuated strain of Mycobacterium bovis and used widely as a vaccination against tuberculosis in high-risk regions. The COVID-19 pandemic has prompted urgent need for novel vaccination or means of reducing disease morbidity and mortality in the global community. Promising new trials aim to ascertain whether this commonly used vaccine has a role in the fight against COVID-19.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
